Other
Pneumococcal Infection
8
Pipeline Programs↗
0
Active Trials↗
4
Companies Involved↗
Pneumococcal Infection is an early-stage landscape with 8 programs across 4 companies. The most active players are Roche, Sanofi, Milestone Pharmaceuticals Inc.. 2 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 21
Analysis
Modality Breakdown
4programs
Small molecule250%
Monoclonal antibody125%
Vaccine125%
Modality classified for 100% of 9 pipeline programs.
Analysis
Trial Status
5
clinical trials
Completed4 · 80%
Unknown status1 · 20%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)